Literature DB >> 15201452

Using antibodies to analyze polyglutamine stretches.

Elizabeth Brooks1, Montserrat Arrasate, Kenneth Cheung, Steven M Finkbeiner.   

Abstract

Expansion of a homomeric stretch of glutamine residues beyond a critical threshold can produce neurodegenerative disease. This observation led to the idea that abnormal polyglutamine stretches can alter protein structure in ways that contribute to disease. Because they are prone to aggregation, proteins with abnormal polyglutamine expansions have been difficult to study with conventional biophysical approaches. Some of these proteins are also very large, complicating efforts to generate them in vitro or to purify them for biochemical studies. An alternative approach has been to use antibodies with known binding specificity as probes of protein folding and protein structure. Antibodies can often bind to specific protein epitopes in situ and are, therefore, one of the few tools that can be used to probe protein structure in a physiological context and in the presence of that protein's normal binding partners. However, antibodies are complex reagents, and an understanding of their binding properties, methods of use, and limitations is needed to interpret results properly. We have developed monoclonal antibodies that specifically recognize expanded polyglutamine stretches in mutant huntingtin. Here, we describe several methods for using one of these antibodies to explore the structure of abnormal polyglutamine expansions and the proteins that contain them.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15201452     DOI: 10.1385/1-59259-804-8:103

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  14 in total

1.  Disease-associated polyglutamine stretches in monomeric huntingtin adopt a compact structure.

Authors:  Clare Peters-Libeu; Jason Miller; Earl Rutenber; Yvonne Newhouse; Preethi Krishnan; Kenneth Cheung; Danny Hatters; Elizabeth Brooks; Kartika Widjaja; Tina Tran; Siddhartha Mitra; Montserrat Arrasate; Luis A Mosquera; Dean Taylor; Karl H Weisgraber; Steven Finkbeiner
Journal:  J Mol Biol       Date:  2012-01-28       Impact factor: 5.469

2.  Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis.

Authors:  Holly B Kordasiewicz; Lisa M Stanek; Edward V Wancewicz; Curt Mazur; Melissa M McAlonis; Kimberly A Pytel; Jonathan W Artates; Andreas Weiss; Seng H Cheng; Lamya S Shihabuddin; Gene Hung; C Frank Bennett; Don W Cleveland
Journal:  Neuron       Date:  2012-06-21       Impact factor: 17.173

3.  Crystallization and diffraction properties of the Fab fragment of 3B5H10, an antibody specific for disease-causing polyglutamine stretches.

Authors:  Clare Peters-Libeu; Yvonne Newhouse; Preethi Krishnan; Kenneth Cheung; Elizabeth Brooks; Karl Weisgraber; Steven Finkbeiner
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-11-24

4.  Quantitative relationships between huntingtin levels, polyglutamine length, inclusion body formation, and neuronal death provide novel insight into huntington's disease molecular pathogenesis.

Authors:  Jason Miller; Montserrat Arrasate; Benjamin A Shaby; Siddhartha Mitra; Eliezer Masliah; Steven Finkbeiner
Journal:  J Neurosci       Date:  2010-08-04       Impact factor: 6.167

5.  An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice.

Authors:  Brian Wilburn; Dobrila D Rudnicki; Jing Zhao; Tara Murphy Weitz; Yin Cheng; Xiaofeng Gu; Erin Greiner; Chang Sin Park; Nan Wang; Bryce L Sopher; Albert R La Spada; Alex Osmand; Russell L Margolis; Yi E Sun; X William Yang
Journal:  Neuron       Date:  2011-05-12       Impact factor: 17.173

6.  Gedunin Degrades Aggregates of Mutant Huntingtin Protein and Intranuclear Inclusions via the Proteasomal Pathway in Neurons and Fibroblasts from Patients with Huntington's Disease.

Authors:  Weiqi Yang; Jingmo Xie; Qiang Qiang; Li Li; Xiang Lin; Yiqing Ren; Wenlei Ren; Qiong Liu; Guomin Zhou; Wenshi Wei; Hexige Saiyin; Lixiang Ma
Journal:  Neurosci Bull       Date:  2019-08-20       Impact factor: 5.203

7.  Monoclonal antibodies recognize distinct conformational epitopes formed by polyglutamine in a mutant huntingtin fragment.

Authors:  Justin Legleiter; Gregor P Lotz; Jason Miller; Jan Ko; Cheping Ng; Geneva L Williams; Steve Finkbeiner; Paul H Patterson; Paul J Muchowski
Journal:  J Biol Chem       Date:  2009-06-02       Impact factor: 5.157

8.  Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice.

Authors:  Xiaofeng Gu; Erin R Greiner; Rakesh Mishra; Ravindra Kodali; Alex Osmand; Steven Finkbeiner; Joan S Steffan; Leslie Michels Thompson; Ronald Wetzel; X William Yang
Journal:  Neuron       Date:  2009-12-24       Impact factor: 17.173

9.  Formation and toxicity of soluble polyglutamine oligomers in living cells.

Authors:  Patrick Lajoie; Erik Lee Snapp
Journal:  PLoS One       Date:  2010-12-28       Impact factor: 3.240

10.  Identifying polyglutamine protein species in situ that best predict neurodegeneration.

Authors:  Jason Miller; Montserrat Arrasate; Elizabeth Brooks; Clare Peters Libeu; Justin Legleiter; Danny Hatters; Jessica Curtis; Kenneth Cheung; Preethi Krishnan; Siddhartha Mitra; Kartika Widjaja; Benjamin A Shaby; Gregor P Lotz; Yvonne Newhouse; Emily J Mitchell; Alex Osmand; Michelle Gray; Vanitha Thulasiramin; Frédéric Saudou; Mark Segal; X William Yang; Eliezer Masliah; Leslie M Thompson; Paul J Muchowski; Karl H Weisgraber; Steven Finkbeiner
Journal:  Nat Chem Biol       Date:  2011-10-30       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.